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Objective: To review available evidence and examine issues surrounding the use of advanced 
antiplatelet therapy in an effort to provide a practical guide for emergency physicians caring for 
patients with acute coronary syndromes (ACS).
Data Sources: American College of Cardiology/American Heart Association (ACC/AHA) 2007 
guidelines for the management of patients with unstable angina (UA) and non-ST-segment elevation 
myocardial infarction (NSTEMI), AHA/ACC 2007 focused update for the management of patients with 
STEMI, selected clinical articles identified through the PubMed database (1965-February 2008), and 
manual searches for relevant articles identified from those retrieved.
Study Selection: English-language controlled studies and randomized clinical trials that assessed the 
efficacy and safety of antiplatelet therapy in treating patients with all ACS manifestations.
Data Extraction and Synthesis: Clinical data, including treatment regimens and patient 
demographics and outcomes, were extracted and critically analyzed from the selected studies and 
clinical trials. Pertinent data from relevant patient registries were also evaluated to assess current 
clinical practice.
Conclusions: As platelet activation and aggregation are central to ACS pathology, antiplatelet 
agents are critical to early treatment. A widely accepted first-line treatment is aspirin, which acts to 
decrease platelet activation via inhibition of thromboxane A2 synthesis. Thienopyridines, which inhibit 
ADP-induced platelet activation, and glycoprotein (GP) receptor antagonists, which bind to platelet 
GP IIb/IIIa receptors and hinder their role in platelet aggregation and thrombus formation, provide 
complementary mechanisms of platelet inhibition and are often employed in combination with aspirin. 
While the higher levels of platelet inhibition that accompany combination therapy improve protection 
against ischemic and peri-procedural events, the risk of bleeding is also increased. Thus, the 
challenge in choosing appropriate therapy in the emergency department lies in balancing the need for 
potent platelet inhibition with the potential for increased risk of bleeding and future interventions the 
patient is likely to receive during the index hospitalization.
[WestJEM. 2009;10:163-175.]
INTRODUCTION
Acute coronary syndrome (ACS) describes a spectrum of 
atherothrombosis, including unstable angina (UA), non−ST-
segment elevation myocardial infarction (NSTEMI) and 
ST-segment elevation myocardial infarction (STEMI). As 
treatment decisions are driven by ACS type and severity, 
initial risk stratification in the emergency department 
(ED) is essential. In addition to historical factors and 
hemodynamic stability, electrocardiographic and cardiac 
biomarker findings play an important role in differentiating 
UA/NSTEMI from STEMI (Figure 1). Patients with acute 
STEMI are candidates for immediate reperfusion therapy Volume X, n o . 3  :  August 2009                                                   164                                      Western Journal of Emergency Medicine
with adjunctive antiplatelet and antithrombotic therapy. The 
optimal strategy (percutaneous coronary intervention [PCI] 
vs. fibrinolysis) depends on the patient’s clinical condition, 
timing of presentation, and the availability of interventional 
resources. In patients with UA/NSTEMI, diagnostic tools such 
as the 7-point Thrombolysis in Myocardial Infarction (TIMI) 
risk score can be used for semi-quantitative assessment of 
the risk of cardiac ischemic complications, where the risk 
of mortality or adverse cardiovascular events increases 
with the scale score.1 It is recommended that high- and 
intermediate-risk UA/NSTEMI patients be managed with an 
early invasive strategy (i.e., diagnostic angiography followed 
by revascularization [PCI or coronary artery bypass graft 
(CABG)]).2,3 The choice of optimal revascularization depends 
on the patient’s coronary anatomy, left ventricular function, 
and the presence of co-morbidities such as diabetes. Lower-
risk patients can receive medical management, with diagnostic 
angiography deferred unless deterioration occurs.3
Since platelet activation and aggregation are pivotal 
to ACS pathology, antiplatelet therapy, including aspirin, 
thienopyridines and glycoprotein IIb/IIIa receptor 
inhibitors (GPIs), is central to ACS treatment. Aspirin, 
which inhibits platelet activation by irreversibly binding to 
cyclooxygenase-1, is widely accepted as first-line treatment 
in ACS patients.2 By irreversibly binding the platelet P2Y12 
receptor, thienopyridines inhibit adenosine disphosphate-
mediated platelet activation. GPIs prevent activated platelets 
from cross-linking with fibrinogen, and ultimately decrease 
the trapping of red blood cells that leads to early vessel 
thrombus formation, obstruction, and/or distal small vessel 
embolization. “Dual” antiplatelet therapy (aspirin plus GPIs or 
aspirin plus thienopyridines) is appropriate in some patients, 
while in others, “triple” therapy including all three agents is 
suitable. 
Emergency physicians (EPs) must choose appropriate 
antiplatelet therapy based on the underlying risk of ischemic 
complications and the anticipated course of treatment, i.e. 
medical vs. interventional management.4 Ideally, evidence-
based, predetermined ACS protocols should be in place so 
that optimal antiplatelet therapy can occur concurrently with 
maximum protection against bleeding complications. Ongoing 
collaboration among EPs, cardiologists, hospitalists and 
cardiovascular surgeons will undoubtedly improve care for 
ACS patients. Data from CRUSADE, a national health quality 
improvement initiative, showed significant improvement 
in adherence to guideline recommendations for ACS 
management in the acute setting, as participating hospitals 
developed more thorough cross-disciplinary pathways and 
protocols.5 It is through such institutional-level collaboration 
that EPs can be empowered to initiate early, appropriate 
anti-ischemic therapy rather than being dependent on the 
individual, often varied, preferences of on-call specialists.
In addition to disease-related ischemia and necrosis, 
high-risk patients who undergo angiography face the potential 
added burden of periprocedural ischemia. It is hypothesized 
that microvascular embolization downstream of the target 
vessel plays a predominant role in the development of 
periprocedural infarction risk.6 Hence, it is important to 
recognize the adjuvant role of pre-catheterization (“upstream”) 
antiplatelet agents and anticoagulation during coronary 
intervention to offer protection against both disease-related 
and periprocedural ischemic insults. Appropriate therapy 
must balance the need for potent platelet inhibition with the 
potential for increased bleeding. 
This review aims to examine issues and barriers 
surrounding antiplatelet therapy use and to provide a practical 
guide for EPs regarding their optimal use in ACS patients. 
While not a purely systematic review, we sought to identify 
relevant controlled studies and randomized clinical trials 
that assessed the efficacy and safety of antiplatelet therapy 
in treating patients with all ACS manifestations. Other data 
sources included 1) the 2007 American College of Cardiology/
American Heart Association (ACC/AHA) ACS treatment 
guidelines, 2) relevant clinical data extracted from patient 
registries, and 3) selected clinical articles identified through 
the PubMed database (1965-February 2008) using appropriate 
search terms (e.g. acute coronary syndrome, antiplatelet 
agents, atherosclerosis, blood platelets, myocardial infarction, 
thrombosis).
Variability of platelet response
Available secondary prevention therapies do not provide 
cures. They decrease associated risks. Despite receiving 
“adequate” antiplatelet therapy, approximately 8-10% of 
patients experience recurrent cardiovascular ischemic events 
after ACS.7-9 This phenomenon is loosely referred to as 
“resistance” without a clear, consensus definition.10,11 In most 
Slattery et al.  Platelet Inhibition with Bleeding Risk in ACS
Figure 1. Spectrum of acute coronary syndromes. Adapted with 
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instances, what is described as resistance is actually either 
hyporesponsiveness to therapy, which falls under platelet 
response variability, or patient non-adherence, which may 
or may not be obvious.12,13 There are many potential reasons 
for platelet response variability, including adherence, non-
absorption, and genetic polymorphisms (Table 1).
True pharmacological resistance is probably uncommon 
and likely the result of genetic polymorphism. Some 
evidence suggests that variability in cytochrome P450-
dependent enzyme activity due to genetic polymorphism may 
contribute to inter-patient variation in aspirin and clopidogrel 
response.14,15 ACS patients are likely to be taking multiple 
medications for co-morbid conditions, including statins 
and/or calcium-channel blockers, that are metabolized by 
cytochrome P3A4 (CYP 3A4). Non-dihydropyridines such 
as verapamil and diltiazen are known to inhibit CYP 3A4, 
and most statins, with the exception of pravastatin, compete 
with clopidogrel for binding to CYP 3A4; this could lead 
to reduced metabolism or clearance of one or both of the 
drugs involved.16 Conversely, a study conducted in healthy 
volunteers showed that St. John’s Wort amplified the effects 
of clopidogrel, turning non-responders into responders.17 
Recently, the FDA reported that additional studies would be 
conducted to better characterize the impact of genetic factors 
and concomitant administration of other drugs on the efficacy 
of clopidogrel.18
Laboratory platelet aggregation tests, traditionally used 
to evaluate bleeding disorders, have recently been employed 
to correlate ex vivo results of antiplatelet therapy with clinical 
outcomes. However, using these inhibition of platelet activity 
(IPA) results is problematic and currently clinically non-
interpretable, partly due to the lack of a standard test for IPA. 
For each given test, there is considerable variation among 
laboratories as the methodology is difficult to standardize. 
Further, results of these tests are temporally variable for any 
given patient. More importantly, there have been no data 
definitively linking IPA with clinical outcomes. In studies 
of patients presenting to the ED with acute chest pain or 
ACS, the success of platelet function testing in predicting 
the severity of MI or other adverse cardiac events has 
been variable.19,20 In particular, results of IPA tests suggest 
‘resistance’ upwards of 35%; in reality, however, only 8%-
10% of patients show clinical signs of hyporesponsiveness 
or resistance.21 Clearly, platelet response variability to 
antiplatelet therapy is a controversial and widely debated topic 
that requires more research to discern its true clinical impact 
and whether any practice changes are necessary. Such changes 
are likely to occur first in the chronic management of coronary 
artery disease, but at some point in the future may impact ED 
decision-making as well.
Loading Dose
Rapid inhibition of platelet aggregation is often 
accomplished by administering a loading dose of an 
antiplatelet agent. As shown in the CURE,8,22 CREDO,7 and 
CLARITY23,24 trials, as well as a meta-analysis thereof ,24 
addition of a 300-mg clopidogrel loading dose resulted in 
significant relative risk reductions in endpoints among all 
ACS patients, regardless of their intervention strategy (Table 
2). The optimal loading dose of clopidogrel necessary to 
safely achieve rapid platelet inhibition has been an area of 
investigation. Compared to the standard 300-mg loading dose, 
a 600-mg dose has been shown to inhibit platelet aggregation 
more rapidly, reducing the time required to achieve maximum 
platelet inhibition from six to two hours.25-31
Although a higher clopidogrel loading dose more 
rapidly inhibits platelet aggregation, it is unclear whether 
this translates into improved clinical outcomes. In the 
ARMYDA-2 study of UA/NSTEMI patients undergoing 
PCI, a 600-mg clopidogrel loading dose reduced the risk of 
periprocedural events by 50% compared to a 300-mg loading 
dose without increasing the risk of bleeding (Table 2).30 In the 
CLEAR PLATELETS and ISAR-REACT 2 studies, addition 
of a GPI following a 600 mg clopidogrel loading dose further 
reduced the risk of adverse events and myocardial necrosis 
without significantly increasing the risk of bleeding.9,25 
However, the added clinical benefits relative to the safety 
(bleeding risk) of higher loading doses remain to be fully 
established. This is being evaluated in the ongoing CURRENT 
OASIS-7 trial.
Current U.S. guidelines reflect the uncertainty of the 
optimal clopidogrel loading dose. Both the PCI and UA/
NSTEMI guidelines specifically mention this uncertainty.2,32 
The UA/NSTEMI guidelines don’t make a specific 
recommendation, while the PCI guidelines recommend a 
600-mg loading dose.2,32 The STEMI guidelines maintain a 
recommendation of 300 mg for patients receiving fibrinolysis 
or no reperfusion.33 
Loading doses of the recently approved antiplatelet agent, 
prasugrel, have also been assessed. In PRINCIPLE, a 60-mg 
prasugrel loading dose resulted in greater platelet inhibition 
compared to a 600-mg clopidogrel loading dose as early as 30 
minutes after intake.34 Although PRINCIPLE was not powered 
to detect clinical outcomes, hemorrhagic adverse events 
were more common in patients taking prasugrel. The excess 
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Table 1. Factors affecting inter-individual variability in response to 
antiplatelet therapy.
Adherence
Intestinal absorption31
Genetic polymorphism resulting in variable cytochrome P450-
dependent enzyme activity 14,15,17
Pretreatment platelet reactivity72
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Table 2. Selected clinical trials and meta-analyses of relevant antiplatelet therapies. The trials are presented according to the antiplate-
let therapy and ACS type investigated. 
Study Treatment Duration Relative Risk Reduction Safety outcomes
Antiplatelet Therapy vs. Placebo
Acute 
MI
Antithrombotic 
Trialists’ Col-
laboration73
Dependent on 
trial and antiplatelet 
therapy used 
Mean = 1 
month
38 fewer vascular events (SE=5) 
per 1,000 patients treated
1-2 additional extracranial bleeds
Clopidogrel + Aspirin vs. Aspirin alone
NSTEMI CURE8 300 mg loading 
dose clopi + 75 mg/
day clopi + 75-325 
mg/day ASA vs. 75-
325 mg/day ASA + 
Placebo
Mean = 
9 months 
Range = 
3-12 months
20% (95% CI, 0.72-0.90; 
P<0.001) in CV death, IS, or non-
fatal reinfarction at 12 months
1% excess of major bleed-
ing (3.7% vs. 2.7%; RR, 1.38; 
P=0.001) and 0.3% excess of 
life-threatening bleeding (2.1% 
vs. 1.8%; P=0.13) with dual 
therapy vs. ASA alone
PCI PCI-CURE22 300 mg loading 
dose clopi + 75 mg/
day clopi + 75-325 
mg/day ASA vs. 75-
325 mg/day ASA + 
Placebo 
Mean = 
8 months 
Range = 
3-12 months
30% (95% CI, 0.50-0.97; p=0.03) 
for CV death, MI or urgent TVR 
within 30 days
No excess of any bleeding 
between PCI and 30 days, but a 
1.4% excess of minor bleeding 
(RR, 1.68; 95% CI, 1.06-2.68; 
p=0.03) after 30 days with dual 
therapy vs. ASA alone 
CREDO7 300 mg clopi loading 
dose + 75 mg/day 
clopi + 75-325 mg/
day ASA vs. 75-325 
mg/day ASA + 
Placebo
12 months 27% (95% CI, 3.9-44.4%; P=0.02) 
for CV death, MI, or IS at 12 
months
2.1% (8.8% vs. 6.7%; P=0.07) 
increase in the risk of major 
bleeding at 12 months with dual 
therapy vs. ASA alone
STEMI CLARITY23 300 mg clopi loading 
dose + 75 mg/day 
clopi + 75-162 mg 
ASA vs. 75-162 mg 
ASA + Placebo
30 days 36% (95% CI, 24-47%; P<0.001) 
for an occluded infarct-related 
artery upon angiography or death 
or recurrent MI prior to angiog-
raphy; 20% (OR, 0.80; 95% CI, 
0.65-0.97; P=0.03) for CV death, 
recurrent MI, or urgent TVR within 
30 days 
0.2% increase (1.3% vs. 1.1%; 
P=0.64) in the risk of major 
bleeding through 30 days
COMMIT74 75 mg/day clopi + 
162 mg/day ASA vs. 
162 mg/day ASA + 
Placebo
Mean = 15 
days
Max = 28 
days
Quartiles = 
9, 14, and 
21 days
9% (OR, 0.91; 95% CI, 0.86-0.97; 
p=.002) for death, recurrent MI, 
or stroke during hospitalization; 
7% (OR, 0.93; 95% CI, 0.87-0.99; 
p=0.03) for all-cause death during 
hospitalization
0.03% (0.58% vs. 0.55%; 
p=0.59) excess of major bleed-
ing 
0.5% (3.6% vs. 3.1%; p=0.005) 
excess of minor bleeding
600 mg clopidogrel loading dose vs. 300 mg clopidogrel loading dose
PCI ARMYDA-230 600 mg clopi load-
ing dose + 75 mg/
day clopi + 100 mg/
day ASA vs. 300 mg 
clopi loading dose 
+ 75 mg/day clopi + 
100 mg/day ASA
30 days 50% (OR, 0.48; 95% CI, 0.15-
0.97; P=0.044) for periprocedural 
MI with 600 mg vs. 300 mg clopi 
loading dose 
No excess bleeding of any type
Prasugrel + Aspirin vs. clopidogrel + Aspirin
PCI TRITON-TIMI 
3875
60 mg prasugrel 
loading dose + 10 
mg/day prasugrel + 
75-162 mg/day ASA 
vs. 300 mg clopi 
loading dose + 75 
mg/day clopi + 75-
162 mg/day ASA
Median = 
14.5 months
29% (HR, 0.81; 95% CI, 0.73-
0.90; P<0.001) for cardiovascular 
death, non-fatal MI, or non-fatal 
stroke
Excess non-CABG-related TIMI 
major (2.4% vs. 1.8%; P=0.03), 
life-threatening (1.4% vs. 0.9%; 
P=0.01), major or minor (5.0% 
vs. 3.8%; P=0.002) and CABG-
related TIMI major (13.4% vs. 
3.2%; P<0.001) bleeding
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bleeding associated with prasugrel was more pronounced in 
TRITON, in which efficacy and safety were compared in PCI 
patients receiving prasugrel or clopidogrel (standard 300-
mg dose); in this study, all classes of TIMI bleeding were 
significantly greater in patients taking prasugrel.35 In light of 
these findings, the U.S. prescribing information for prasugrel 
includes a black box warning highlighting its associated 
bleeding risks. Specifically, prasugrel is contraindicated 
in patients with active pathological bleeding or a history 
of stroke or TIA, should not be given to patients likely to 
undergo CABG, and is generally not recommended for 
patients aged ≥75 years. 
CABG
In ACS patients who undergo CABG, the addition of 
clopidogrel to aspirin increases bleeding risk if surgery 
is performed within five days after discontinuation.8 A 
dilemma thus arises, as it is difficult to predict prior to 
diagnostic angiography which patients will require urgent, 
early CABG.8,36 The EP can take one of two approaches to 
starting clopidogrel: 1) Initiate clopidogrel in the ED in all 
high-risk UA/NSTEMI patients, with a view to withdraw 
before emergency CABG or five to seven days before semi-
elective or elective CABG; or 2) defer clopidogrel treatment 
until after angiography, therefore avoiding treatment in 
patients who require emergency CABG. The first strategy, 
recommended by the European Society of Cardiology 
(ESC),37 offers the advantages of reducing early ischemic 
events (relative risk reduction of 20%) and optimal timing 
for pre-PCI administration, but at the cost of increased peri-
operative bleeding for patients who undergo early CABG.36,38 
The second strategy offers the advantage of avoiding excess 
bleeding during early CABG, but at the cost of ischemic 
events and loss of pre-treatment benefit in PCI patients.8,39 
It is important to remember the CRUSADE data, 
where only 12% of UA/NSTEMI patients underwent 
GP IIb/IIIa Inhibitor + ASA vs. ASA alone
NSTEMI Meta-analy-
sis56
Dependent on trial Dependent 
on trial
9% (OR, 0.91; 95% CI, 0.84-0.98; 
p=0.015) in death or MI at 30 
days
1% (2.4% vs. 1.4%; p<0.0001) 
excess of major bleeding
PCI Meta-analy-
sis76
Dependent on trial Dependent 
on trial
31% (RR, 0.69; 95% CI, 0.53-
0.90) 21% (RR, 0.79; 95% CI, 
0.64-0.97) in death at 30 days 
and 6 months, respectively 
Excess major bleeding only 
when heparin continued after 
PCI (RR, 1.70; 95% CI, 1.36-
2.40 vs. RR, 1.02; 95% CI, 
0.85-1.24)
GP IIb/IIIa Inhibitor + Fibrinolytic vs. Fibrinolytic alone
STEMI INTEGRITI77 180 mcg/kg bolus 
eptifibatide + 2 mcg/
kg/min infusion + 
180 mcg/kg bo-
lus eptifibatide 10 
minutes later + 0.27 
mg/kg TNK +ASA 
vs. 0.54 mg/kg TNK 
+ ASA + Placebo
60 minutes 10% (59% vs. 49%; p=0.15) 
increase in TIMI grade 3 flow at 
60 minutes
5.1% (7.6% vs. 2.5%; p=0.14) 
excess of major hemorrhage
9.2% (13.4% vs. 4.2%; p=0.02) 
excess of transfusions
SPEED78 0.25 mg/kg bolus 
abciximab + 12 hour 
0.125 mg/kg/min 
abciximab infusion 
+ 2 5U boluses of 
reteplase + ASA vs. 
2 10 U boluses of 
reteplase + ASA + 
Placebo
12 hours 7% (54% vs. 47%; p=0.39) 
increase in TIMI grade 3 flow at 
60-90 minutes
6.1% (9.8% vs. 3.7%; p=0.11) 
excess of major bleeding
ARMYDA-2, Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty; ASA, aspirin; clopi, clopidogrel; CLARITY, Clopidogrel as 
Adjunctive Reperfusion Therapy; COMMIT, Clopidogrel and Metoprolol in Myocardial Infarction Trial; CREDO, Clopidogrel for the Reduction of Events 
During Observation; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events; CV, cardiovascular; GP, glycoprotein; INTEGRITI, Integrilin 
and Tenecteplase in Acute Myocardial Infarction; IS, ischemic stroke; MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; OR, 
odds ratio; PCI, percutaneous coronary intervention; RR, relative risk; SE, standard error; SPEED, Strategies for Patency Enhancement in the Emer-
gency Department; STEMI, ST elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction; TRITON, Trial to Assess Improvement in 
Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel; TVR, target vessel revascularization.
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CABG during their index hospitalization.40 Other studies 
estimate rates of CABG between 8% and 25% during index 
hospitalization.8,41-44 Emergency CABG rates are seemingly 
lower, from 0.3% to 0.6%.45 Since the majority of patients 
are suitable for PCI or medical management, most high-risk 
ACS patients would thus benefit from early dual antiplatelet 
inhibition. Furthermore, among patients in CURE who 
underwent CABG, lower ischemic event rates were observed 
with clopidogrel treatment before CABG.36 Taking these 
considerations into account, it has been suggested that 
most patients requiring CABG will benefit from initiating 
clopidogrel and aspirin on admission (i.e. in the ED) and then 
stopping clopidogrel five days before surgery to minimize 
bleeding risk (Figure 2).36,46 Even if urgent CABG is required, 
evidence indicates that an experienced surgeon can perform 
CABG within five days of clopidogrel washout via judicious 
use of a bleeding management algorithm.47 One study found 
that CABG performed within five days of clopidogrel washout 
resulted in postoperative mortality rates similar to patients 
who were not exposed to clopidogrel within five days before 
CABG.47
Patients with hemodynamic instability (cardiogenic 
shock), mechanical complications (acute mitral regurgitation), 
diabetes, impaired left ventricular function, concomitant 
vascular disease, and multivessel disease are at higher risk 
for urgent CABG.2,48 As shown in the Bypass Angioplasty 
Revascularization Investigation study of patients with 
diabetes,49 such patients may have improved survival with 
CABG compared to PCI. It would therefore be prudent to 
withhold clopidogrel in these patients. For patients for whom 
clopidogrel pre-treatment is withheld pending angiography, 
data from ISAR-REACT 2 suggest that GPIs be administered 
upstream of the catheterization lab in troponin-positive 
patients 9
Based on an analysis of NSTEMI patients from the 
TACTICS-TIMI-18 trials, Sadanandan et al.50 developed 
a predictive risk score to identify patients who are likely 
to require CABG during index hospitalization. Mehta 
et al.51 have also developed a multivariate model, based 
on CRUSADE data, identifying 13 presenting clinical 
characteristics significantly associated with undergoing 
CABG during initial hospital stay. However, identification 
in the ED of patients likely to need urgent CABG remains 
problematic as these prediction scores are often unreliable 
prior to diagnostic angiography. Because of the difficulty 
in predicting which ACS patients will require emergency 
CABG, it is essential that emergency physicians, cardiologists, 
cardiovascular surgeons, and hospitalists develop clear, 
institution-specific indications for clopidogrel and GPI 
administration. Such collaboration decreases reliance on 
personal preferences and empowers emergency physicians 
to initiate care and gain ischemia-related reductions while 
simultaneously maximizing patient safety.
Safety Considerations
The risk of bleeding is the most important safety 
consideration when initiating antiplatelet therapy. This risk 
must be weighed against observed clinical benefits in all 
ACS patients. As might be expected based on higher levels 
of platelet inhibition, bleeding risk is increased by combining 
antiplatelet agents (Table 2). Among ACS patients, adding 
clopidogrel to aspirin is associated with an absolute 0.2% to 
1.0% increase in major bleeding.52 However, the statistical 
significance of this increased bleeding varied among the 
trials. This may be partly due to the definition used to 
classify bleeding events. For example, the excess bleeding in 
CURE was significant when the OASIS scale was used but 
insignificant using the TIMI and GUSTO scales.8 Importantly, 
even using the stringent OASIS scale, life-threatening 
bleeding was not significantly greater among dual aspirin and 
clopidogrel recipients in CURE. 
In contrast to the well-established safety and efficacy data 
of dual treatment with aspirin and clopidogrel, data related 
to dual therapy with aspirin and prasugrel are only emerging, 
and their overall clinical significance is yet unknown. In 
TRITON, the superior efficacy of prasugrel and aspirin was 
accompanied by significant excesses of non-CABG-related 
TIMI major and minor bleeding, life-threatening and fatal 
bleeding, bleeding requiring transfusion, and CABG-related 
TIMI major bleeding (Table 2).35 The risk of bleeding was 
particularly prominent in patients with a history of stroke 
or TIA and those aged ≥75 years or with a body weight <60 
Figure 2. Suggested antiplatelet therapy management algorithm 
for patients presenting to the ED with ACS and requiring CABG. 
*Consider withholding antiplatelet therapy in patients at a high risk 
of CABG (e.g., those with cardiogenic shock, mitral regurgitation, 
impaired left ventricular function). ACS, acute coronary syndrome; 
CABG, coronary artery bypass grafting; ED, emergency 
department.
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kg. The resultant unfavorable net benefit in these patient 
subgroups led to the inclusion of the aforementioned black 
box warning in the prasugrel prescribing information. 
Additional data are required to fully establish the net benefit 
of dual therapy with aspirin and prasugrel.
The safety profiles of AZD6140 and cangrelor, two 
emerging antiplatelet agents which are reversible inhibitors 
of the P2Y12 receptor, also remain to be determined. In 
early trials, AZD6140 induced hypotension and dyspnea, 
potentially problematic side effects that may mimic symptoms 
of recurrent atherothrombotic events.53 Additionally, AZD610 
has a higher IPA than clopidogrel and may lead to an increased 
risk of bleeding in certain patient populations.53 While 
cangrelor did not show significant excess bleeding in early 
trials,54,55 more data are needed. 
GPI inhibition is associated with a small, significant 
increased incidence of bleeding, most commonly at the 
vascular access site (Table 2). In a meta-analysis, GPI use in 
UA/NSTEMI patients was associated with a significant excess 
of major bleeding complications (2.4% vs. 1.4%, p<0.0001), 
though intracranial bleeding was not increased significantly.56 
It is important to note, however, that this increased bleeding 
risk was offset by significant reductions in death and MI, 
particularly in high-risk patients. Among STEMI patients 
treated by fibrinolysis, GPI therapy is not associated with a 
net clinical benefit as major bleeding is significantly increased 
in the absence of any mortality reductions (Table 3).57,58 In 
contrast, the ADMIRAL59 and CADILLAC60 studies showed 
that benefits from upstream GPI therapy in PCI patients 
were not compromised by any important increased bleeding 
risk. In the ACUITY trial,61 which investigated an early 
invasive strategy in UA/NSTEMI patients, the combination 
of bivalirudin, a direct thrombin inhibitor, with GPI therapy 
was associated with comparable clinical outcomes and a lower 
bleeding risk compared with heparin plus GPI therapy.
Overall, a large body of evidence supports an acceptable 
safety profile for dual antiplatelet therapy with aspirin and 
clopidogrel in all ACS patients, a differential safety profile 
with GPIs, and an unclear safety profile for the novel agents 
prasugrel, AZD6140, and cangrelor. 
Evidence-based, practical solutions for antiplatelet therapy
The 2007 ACC/AHA guidelines recommend that all 
ACS patients receive aspirin and clopidogrel (loading 
dose followed by a maintenance dose) as soon as possible 
regardless of reperfusion strategy (Table 3).2 Antiplatelet 
therapy should not be withheld prior to catheterization. If the 
patient has already received clopidogrel and elective CABG is 
deemed necessary, clopidogrel should be discontinued for five 
to seven days prior to surgery in order to balance antiplatelet 
efficacy with bleeding risk. The addition of a GPI depends 
on the management strategy and risk level of the patient.2 
In UA/NSTEMI patients, a GPI should be given upstream 
of, or immediately prior to, PCI. The guidelines advocate 
GPI administration as early as possible in STEMI patients 
undergoing PCI,32,33,62,63 which supports initiating treatment in 
the ED. 
Results from various studies supporting these guidelines are 
of particular interest to EPs. One example is the finding from 
CURE supporting early initiation of dual antiplatelet inhibition 
in UA/NSTEMI patients. A statistically significant benefit of 
dual antiplatelet therapy over aspirin alone in reducing ischemic 
events was evident as early as 24 hours after randomization, 
with the curves separating qualitatively at 12 hours (Figure 3).8 
Other evidence supports pretreatment with a clopidogrel loading 
dose prior to PCI.7,22 Among UA/NSTEMI patients in CREDO 
and those undergoing PCI in CURE, adding a clopidogrel 
loading dose resulted in significant relative risk reductions in 
endpoints (Table 2).22 The CLARITY and COMMIT trials, 
which evaluated clopidogrel treatment in conjunction with 
fibrinolytics, aspirin and heparin in STEMI patients, reported 
significant cardiovascular event reductions in patients pretreated 
with clopidogrel (Table 2).23 
CREDO also raised the issue of timing in UA/NSTEMI 
patients, suggesting that longer intervals between dosing 
and PCI might show greater benefit, ostensibly by allowing 
clopidogrel to achieve maximum platelet inhibition.7 It should 
be emphasized that one of the most compelling reasons to 
initiate clopidogrel therapy as early as possible is to decrease 
periprocedural ischemia.30 In the ARMYDA-2 trial, patients 
were randomized to loading doses of either 600-mg or the 
conventional 300-mg 4-8 hours prior to angiography.30 The 
primary endpoint was the 30-day occurrence of death, MI, or 
target vessel revascularization. The primary endpoint occurred 
in 4% of patients in the high-loading dose group versus 12% 
of those in the conventional-loading dose group (P=0.041) and 
was due entirely to periprocedural MI. However, in a small 
study of patients with ACS undergoing stent implantation, 
no difference was found with three days of clopidogrel 
pretreatment compared with standard post-procedural 
Figure 3. Cardiovascular death, myocardial infarction, stroke and 
severe ischemia within the first 24 hours after randomization to aspirin 
plus placebo or aspirin plus clopidogrel in the CURE study. With per-
mission. Yusuf et al. Early and Late Effects of Clopidogrel in Patients 
with Acute Coronary Syndromes. Circulation. 2003;107:966-72.80
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treatment in troponin I or creatinine kinase-MB serum levels 
up to 24 hours after PCI.64 
Although it is important for EPs to appreciate the added 
periprocedural protection that upstream administration of 
advanced antiplatelet therapy affords their ACS patients, 
the ideal timing of clopidogrel initiation is uncertain. The 
guidelines recommend administration as soon as possible, 
and as the time from administration to PCI increases, so does 
the periprocedural protection. The ARMYDA-2 trial gave 
a loading dose 4-6 hours prior to PCI, but the EP is often 
dealing with a 90-minute treatment window, making the 
ARMYDA-2 results relevant primarily to those ACS patients 
not going emergently for PCI.
Similarly, the optimal timing for GPI initiation prior 
to PCI is unclear.4 In PURSUIT, the reduction in death and 
MI was inversely associated with the time from symptom 
onset to GPI initiation;4 however, data from PRISM and 
NRMI 4 suggest no difference in outcomes as long as the 
drug was initiated within 24 hours of symptom onset.65,66 
In the absence of clear evidence, ED physicians must 
carefully weigh each individual patient’s characteristics and 
clinical symptoms when making a decision concerning GPI 
initiation. 
The adjunctive use of GPIs in STEMI patients depends 
on the planned treatment course. In the setting of PCI, the 
ADMIRAL study showed a significant reduction in death/
reinfarction/urgent revascularization at both 30 days and 
six months when adjunctive abciximab was administered 
prior to the procedure.59 The CADILLAC study confirmed 
the protective effect of abciximab in the short term 
(35% relative risk reduction for death, MI, target vessel 
revascularization or stroke at 30 days), although this benefit 
Table 3. Current antiplatelet therapy recommendations and adverse effects. The data is presented according to class of antiplatelet 
therapy and ACS condition. Recommendations were compiled from references 2, 32, 33, 63 and 79.
Antiplatelet  Condition Recommendation Adverse Effects Comments
Thromboxane A2 Inhibitors
Aspirin NSTEMI, 
PCI, and 
STEMI
Daily consumption initiated immediately 
following symptom onset and continued 
indefinitely by all patients with a history 
of CAD or ACS and without aspirin 
allergy
1. Increased risk of bleeding 
complications; 2. Monothera-
py associated with high risk of 
stent thrombosis after PCI
1. The most studied and well-
established of the antiplatelet 
therapies; 2. Efficacious; 3. 
Good safety profile; 4. Low cost; 
5. Aspirin resistance may occur
Thienopyridine Inhibitors
Clopidogrel  NSTEMI, 
PCI, and 
STEMI
An alternative in secondary prevention 
if aspirin is contraindicated
1. 10 years of experience; 2. 
Well-established efficacy in pre-
venting adverse events following 
revascularization when used with 
aspirin; 3. Clopidogrel resistance 
is a documented phenomenon 
NSTEMI 1. A loading dose followed by daily 
maintenance for at least 1 month and 
ideally up to 1 year as part of early 
conservative management; 2. Withhold 
in the 5-7 days prior to CABG
1. Increased risk of bleeding 
when used in combination 
with aspirin; 2. Increased risk 
of bleeding when used in the 
5-7 days prior to CABG
PCI A loading dose initiated prior to PCI, fol-
lowed by maintenance dose daily for at 
least 1 month, and ideally up to 1 year, 
following BMS implantation and at least 
12 months following DES implantation
Increased risk of bleeding 
when used in combination 
with aspirin
STEMI 1. A loading dose followed by daily 
maintenance for at least 14 days; 2. 
Withhold in the 5-7 days prior to CABG
Increased risk of bleeding 
when used <5 days prior to 
CABG
Prasugrel NSTEMI None Under assessment
PCI None Increased risk of bleeding, 
especially in patients with a 
history of stroke or TIA, those 
aged ≥75 years, and those 
with a body weight <60 kg
1. Higher IPA than clopidogrel, 
which could mean greater risk of 
bleeding; 2. No statistically pow-
ered evidence showing superior-
ity over clopidogrel
STEMI None Under assessment
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was no longer apparent at one year.60 Data from ADMIRAL 
and CADILLAC, conducted in the PCI setting, show that 
the protective benefits of pre-procedural abciximab are not 
compromised by any important increase in bleeding risk. In 
contrast, the ASSENT-3 and GUSTO V trials demonstrated 
that the combination of a GPI with half-dose thrombolytic 
reduced ischemic events but increased bleeding; furthermore, 
there was no short- or long-term survival benefit.67-71 These 
findings suggest that adding a GPI is not justified during 
fibrinolytic treatment of STEMI.
GP IIb/IIIa Inhibitors
Abciximab NSTEMI Not recommended No benefit
PCI 1. Initiate as soon as possible as ancil-
lary therapy in high risk patients under-
going PCI only if there is no appreciable 
delay to angiography; otherwise, eptifi-
batide or tirofiban is preferred; 2. Early 
initiation to improve pre-procedural TIMI 
grade 3 flow
1. Insignificant excess risk 
of bleeding; 2. Significantly 
increased risk of disabling 
stroke
1. Abciximab has not been 
shown to reduce the risk of tar-
get vessel reocclusion; 2. Com-
bination abciximab and reteplase 
or tenecteplase should not be 
given to patients aged >75 years 
due to an increase risk of ICH
STEMI May be considered for reperfusion in 
combination with half-dose reteplase or 
tenecteplase in high-risk patients
Increased risk of ICH in pa-
tients aged ≥75 years
Treatment does not translate to 
survival advantage at 30 days or 
1 year
Eptifibatide NSTEMI May be considered in high-risk patients 
undergoing early conservative manage-
ment
Increased risk of bleeding Benefits seem to be restricted to 
high-risk patients
PCI Initiate as soon as possible as ancillary 
therapy 
Increased risk of minor bleed-
ing
Benefits seem to be restricted to 
high-risk patients
STEMI None
Tirofiban NSTEMI May be considered in high-risk patients 
undergoing early conservative manage-
ment
Increased risk of bleeding Benefits seem to be restricted to 
high-risk patients
PCI Initiate as soon as possible as ancillary 
therapy 
1. Increased risk of death, 
MI, stroke, and target vessel 
failure at 30 days when used 
with paclitaxel-eluting stents; 
2. Insignificant risk of major 
bleeding when used in combi-
nation with heparin
Benefits seem to be restricted to 
high-risk patients
STEMI None
Non-thienopyridine P2Y12 Inhibitors
AZD6140 NSTEMI None 1. Bleeding risk similar to 
clopidogrel; 2. Higher rates of 
dyspnea, hypotension, and 
nausea compared to clopi-
dogrel
1. Higher IPA, which could 
mean greater risk of bleeding 
in other patient populations; 2. 
Short half-life; 3. No published 
evidence showing superiority 
over clopidogrel
PCI None Assessment underway
STEMI None Assessment underway
Cangrelor NSTEMI None Insignificant excess risk of 
bleeding
1. Does not require liver metabo-
lism to produce active compound 
and can therefore be used IV; 2. 
High IPA
PCI None  Assessment underway
STEMI None  Assessment underway
ACS, acute coronary syndrome; BMS, bare metal stent; CABG, coronary artery bypass grafting; CAD, coronary artery disease; DES, drug-eluting stent; 
GP, glycoprotein; ICH, intracranial hemorrhage; MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary 
intervention; STEMI, ST elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction
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CONCLUSION
The EP’s role in treating ACS patients is to provide 
rapid, accurate diagnosis and institute timely, risk-directed 
treatment. Increasing the potency of platelet inhibition by 
adding a thienopyridine or GPI to standard therapy early in 
the treatment course improves protection against ischemic 
and periprocedural events but must be balanced against any 
unjustifiable increase in bleeding risk. Clopidogrel plus aspirin 
is a safe and effective therapy recommended by national 
guidelines for use in ACS patients, regardless of treatment 
strategy (Table 4).
Choice and timing of antiplatelet therapy in the ED 
must also take into consideration future interventions the 
patients may receive during their hospital course. In addition 
to standard aspirin therapy, early initiation of clopidogrel in 
the ED is often justified in ACS patients, regardless of their 
subsequent treatment strategy (medical or interventional). 
However, care should be taken regarding patients who are 
highly likely to require early CABG. Early administration 
of a GPI is also often justified in ACS patients in the PCI 
setting and in high-risk UA/NSTEMI patients in whom 
medical management is planned. Results from the ASSENT-3 
and GUSTO-V trials do not support a favorable balance of 
benefit over bleeding risk for GP inhibition in STEMI patients 
undergoing fibrinolysis. This finding illustrates the complexity 
of balancing increased antiplatelet potency with bleeding risk.
Emerging investigational antiplatelet agents may show 
promise in ACS treatment; however, use of these agents 
should be approached with caution. Although touting 
increased IPA, it should be recalled that traditionally this has 
been a measure of bleeding, not potency. Therefore, long-
term risks for bleeding and compliance may become issues. 
As the science of emergency cardiology care continues to 
mature and evolve at a rapid pace, continuous, evidence-
based, multidisciplinary collaboration is paramount for 
delivering optimal and safe care for ACS patients. Given the 
variability in treatment preferences and awareness of guideline 
recommendations, there is an important need for developing 
institutional protocols and order sheets in order to improve 
adherence to treatment guidelines. 
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Table 4. Summary of the Class I recommendations of the American College of Cardiology/American Heart Association (ACC/AHA) 
guidelines for antiplatelet therapy in UA/NSTEMI,2 STEMI,33,63 and PCI32 patients.
UA/STEMI STEMI PCI
Initiate aspirin as soon as possible af- • 
ter hospital presentation and continue 
indefinitely; substitute clopidogrel in 
patients who have aspirin intolerance
Initiate aspirin as soon as possible af- • 
ter hospital presentation and continue 
indefinitely, substitute clopidogrel for 
aspirin in cases of intolerance
Patients already taking preventative as- • 
pirin should take 75 mg-325 mg prior to 
PCI. Patients not currently taking aspirin 
should receive 300 mg -325 mg at least 
2, preferably 24, hours prior to PCI
Add clopidogrel (loading dose followed  • 
by maintenance dose) to aspirin ther-
apy as soon as possible after admis-
sion if an early non-invasive strategy 
is planned and continue clopidogrel for 
at least 1 month and ideally for 1 year
Add clopidogrel (loading dose followed  • 
by maintenance dose) to aspirin therapy 
regardless of the planned reperfusion 
strategy and continue for at least 14 
days in all patients and ≥1 month but ≤9 
months in patients undergoing PCI.
Add 600 mg loading dose of  • 
clopidogrel before or at the time 
of PCI. If fibrinolytic therapy was 
received in the previous 12-24 hours, 
a 300 mg loading dose may be 
considered.
Add clopidogrel (loading dose followed  • 
by maintenance dose) or an intrave-
nous GP IIB/IIIa inhibitor (abciximab if 
there is no delay to angiography and 
PCI is likely; otherwise, eptifibatide or 
tirofiban are preferred) to aspirin if an 
initial invasive strategy is planned
If elective CABG surgery is planned,  • 
withhold clopidogrel for 5-7 days 
beforehand
If elective CABG surgery is planned,  • 
withhold clopidogrel for 5-7 days 
beforehand
UA/STEMI, unstable angina ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction; PCI, percutaneous coronary intervention.
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